Mitotane-driven apoptosis in adrenocortical carcinoma: A molecular insight

Main Article Content

Armagan Akkus
Muge Gulcihan Onal

Abstract

Aim: The aim of this study was to investigate the responses of antiapoptotic Bcl-2 and proapoptotic Bid genes to Mitotane and other chemotherapy drugs in Adrenocortical Carcinoma (ACC) cells. The purpose was to understand the effects of these chemotherapy drugs on apoptosis-related genes in ACC and to identify potential treatment pathways.


Materials and Methods: The study involved the use of ACC cells to assess gene expressions in response to treatment with Mitotane, Etoposide, and Cisplatin. Gene expression levels of Bcl-2 and Bid were measured after drug exposure, providing insight into the modulation of apoptosis pathways by Rt-qPCR.


Results: The results demonstrated that Mitotane notably affected the expression of the proapoptotic Bid gene in ACC cells, promoting apoptosis. Cisplatin increased the expression of the antiapoptotic Bcl-2 gene and decreased the expression of the proapoptotic Bid gene compared to Mitotane.


Conclusion: This study showed that Mitotane, like other chemotherapy drugs, affects the expression of key apoptosis-related genes in ACC cells. Mitotane significantly affected the proapoptotic Bid gene, indicating its potential as a treatment option for ACC. These findings suggest that Mitotane affects ACC cells, highlighting its importance in ACC therapy.

Downloads

Download data is not yet available.

Article Details

How to Cite
Akkus, A., & Onal, M. G. (2024). Mitotane-driven apoptosis in adrenocortical carcinoma: A molecular insight. Annals of Medical Research, 31(2), 101–105. Retrieved from http://annalsmedres.org/index.php/aomr/article/view/4631
Section
Original Articles